Free Trial
NASDAQ:CRSP

CRISPR Therapeutics (CRSP) Stock Price, News & Analysis

CRISPR Therapeutics logo
$56.42 -0.38 (-0.67%)
Closing price 04:00 PM Eastern
Extended Trading
$56.21 -0.21 (-0.37%)
As of 05:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About CRISPR Therapeutics Stock (NASDAQ:CRSP)

Key Stats

Today's Range
$54.93
$56.67
50-Day Range
$33.21
$60.08
52-Week Range
$30.04
$63.68
Volume
2.45 million shs
Average Volume
2.43 million shs
Market Capitalization
$4.87 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$71.75
Consensus Rating
Moderate Buy

Company Overview

CRISPR Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
65th Percentile Overall Score

CRSP MarketRank™: 

CRISPR Therapeutics scored higher than 65% of companies evaluated by MarketBeat, and ranked 367th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    CRISPR Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.53, and is based on 10 buy ratings, 6 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    CRISPR Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about CRISPR Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for CRISPR Therapeutics are expected to grow in the coming year, from ($5.16) to ($4.03) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of CRISPR Therapeutics is -12.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of CRISPR Therapeutics is -12.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    CRISPR Therapeutics has a P/B Ratio of 2.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about CRISPR Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    30.90% of the float of CRISPR Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    CRISPR Therapeutics has a short interest ratio ("days to cover") of 9.4.
  • Change versus previous month

    Short interest in CRISPR Therapeutics has recently increased by 19.29%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    CRISPR Therapeutics does not currently pay a dividend.

  • Dividend Growth

    CRISPR Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    30.90% of the float of CRISPR Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    CRISPR Therapeutics has a short interest ratio ("days to cover") of 9.4.
  • Change versus previous month

    Short interest in CRISPR Therapeutics has recently increased by 19.29%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    CRISPR Therapeutics has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.01 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 16 news articles for CRISPR Therapeutics this week, compared to 11 articles on an average week.
  • Search Interest

    58 people have searched for CRSP on MarketBeat in the last 30 days. This is an increase of 61% compared to the previous 30 days.
  • MarketBeat Follows

    30 people have added CRISPR Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 43% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, CRISPR Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $141,316.00 in company stock.

  • Percentage Held by Insiders

    Only 4.10% of the stock of CRISPR Therapeutics is held by insiders.

  • Percentage Held by Institutions

    69.20% of the stock of CRISPR Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about CRISPR Therapeutics' insider trading history.
Receive CRSP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CRISPR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CRSP Stock News Headlines

A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
See More Headlines

CRSP Stock Analysis - Frequently Asked Questions

CRISPR Therapeutics' stock was trading at $39.36 at the beginning of 2025. Since then, CRSP stock has increased by 43.3% and is now trading at $56.42.

CRISPR Therapeutics AG (NASDAQ:CRSP) released its earnings results on Tuesday, May, 6th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.27) by $0.31. CRISPR Therapeutics's revenue for the quarter was up 71.6% on a year-over-year basis.

CRISPR Therapeutics (CRSP) raised $75 million in an initial public offering (IPO) on Wednesday, October 19th 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays served as the underwriters for the IPO and Guggenheim Securities was co-manager.

CRISPR Therapeutics' top institutional investors include Wealth Enhancement Advisory Services LLC (0.10%), Bouvel Investment Partners LLC (0.04%), Hedges Asset Management LLC (0.03%) and Capital Market Strategies LLC (0.02%). Insiders that own company stock include Samarth Kulkarni, James R Kasinger, Julianne Bruno, John Greene, Raju Prasad and Naimish Patel.
View institutional ownership trends
.

Shares of CRSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that CRISPR Therapeutics investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), DiamondRock Hospitality (DRH), American Water Works (AWK), AU Optronics (AUOTY) and Triple Flag Precious Metals (TFPM).

Company Calendar

Last Earnings
5/06/2025
Today
7/14/2025
Next Earnings (Estimated)
8/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CRSP
CIK
1674416
Fax
N/A
Employees
460
Year Founded
N/A

Price Target and Rating

High Price Target
$120.00
Low Price Target
$32.00
Potential Upside/Downside
+26.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.53
Research Coverage
17 Analysts

Profitability

EPS (Trailing Twelve Months)
($4.52)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$366.25 million
Net Margins
-1,023.64%
Pretax Margin
-1,013.10%
Return on Equity
-20.08%
Return on Assets
-17.13%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
15.64
Quick Ratio
15.64

Sales & Book Value

Annual Sales
$37.31 million
Price / Sales
131.47
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$22.64 per share
Price / Book
2.51

Miscellaneous

Outstanding Shares
86,360,000
Free Float
82,823,000
Market Cap
$4.91 billion
Optionable
Optionable
Beta
1.82

Social Links

A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:CRSP) was last updated on 7/14/2025 by MarketBeat.com Staff
From Our Partners